Allergic bronchopulmonary aspergillosis often requires treatment with oral corticosteroids to control the host response to Aspergillus fumigatus. In a double blind study 25 patients with allergic bronchopulmonary aspergillosis taking maintenance oral corticosteroids were randomly allocated to receive 5 mg natamycin or placebo by nebuliser twice daily for one year. The primary aim of the study was to assess the steroid sparing potential of natamycin. Standardised reductions in corticosteroid dosage were therefore undertaken every five weeks, unless clinically contraindicated. Five patients were withdrawn in the first four months: two (1 natamycin, 1 placebo) died, two (1 natamycin, 1 placebo) had suspected drug reactions, and one (natamycin) was non-compliant. The pretreatment characteristics of the 20 patients (10 in each group) who completed the study were similar, 17 (9 natamycin, 8 placebo) having evidence of recent disease activity. At the end of the study prednisolone dose had been reduced by a similar amount in each group (median natamycin 2 25 mg, placebo 2-5 mg). Evidence of disease activity during the study year (transient shadowing on the chest radiograph, blood eosinophilia, or increases in antibodies to A fumigatus, or any combination of these)-was observed in similar numbers of patients in each group (5 natamycin, 7 placebo). There was no evidence that natamycin conferred benefit on these patients with allergic bronchopulmonary aspergillosis.
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Prolonged oral corticosteroid treatment is often used in patients with allergic bronchopulmonary aspergillosis in an attempt to control the host inflammatory response to Aspergillus fumigatus, but corticosteroids are associated with significant morbidity. '2 A fumigatus is found more frequently in the respiratory tract of patients with untreated allergic bronchopulmonary aspergillosis (58%) and in larger quantities than in patients with other respiratory disease."4 Antifungal agents might therefore reduce the requirement for corticosteroids.
Nebulised antifungal agents, nystatin and natamycin (pimaricin), and nebulised brilliant green have been administered in an attempt to reduce the fungal load.7 The studies that have been reported were inadequately controlled and have shown equivocal evidence of benefit. In a group of eight patients with bronchopulmonary aspergillosis (initial culture positive for A fumigatus) treated with nebulised natamycin (2-5 mg thrice daily for one month and thereafter twice daily) A fumigatus disappeared from the sputum after a median of six (range 4-30) weeks.7 In a further study of four patients with allergic bronchopulmonary aspergillosis not receiving oral corticosteroids oral ketoconazole was associated with improvement in symptoms of asthma and a reduction in antibodies to A fumigatus,' but the risk of hepatotoxicity9 renders ketoconazole unsuitable as a long term alternative to corticosteroids.
In a pilot study six of seven patients with allergic bronchopulmonary aspergillosis treated with nebulised natamycin (2-5 mg thrice daily) and salbutamol were successfully withdrawn from maintenance corticosteroid treatment (5-20 mg prednisolone a day). We therefore set out to determine the corticosteroid sparing effect of natamycin in a controlled trial.
Methods

STUDY DESIGN
Patients were randomly allocated to inhale 5 mg natamycin (Pimafucin, Brocades Ltd) or placebo (0 9% saline) delivered by nebuliser twice daily for 50 weeks in a double blind manner. The 0-5 ml of trial solution (5 mg natamycin or placebo) was diluted with 3 ml 09%o saline and inhaled through a mouthpiece, an Inspiron nebuliser powered by a Portaneb 50 compressor being used. The random treatment allocation was stratified by severity of airflow obstruction and dose of oral corticosteroid at entry to the study according to the minimisation method."
The primary aim of the study was to assess the corticosteroid sparing effect of natamycin. The corticosteroid dosage was therefore reduced every five weeks by one step according to a standard schedule unless this was clinically inappropriate. The steps in this schedule were 20, 15, 10, 7 5, 6, 5, 4, 3, 2, 1, 0 mg of prednisolone. Patients recorded their symptoms, use of the study drug and of beta2 agonist, and moming peak expiratory flow (best of three prebronchodilator results) on a diary card daily. The patients were seen, diary cards reviewed, and investigations performed Currie, Lueck, Milburn, Harvey, Longbottom, Darbyshire, Nunn, Cole Blood eosinophilia (> 0 5 x 109/l) 9 4 No of patients culture positive for Aspergillusfumigatus specific immunoglobulin concentrations to under 50% and over 150% of the initial value were arbitrarily defined as significant decreases and increases. Total immunoglobulins G, A, M, and E were measured in all patients at the beginning and end of the study.
A full blood count, determination of urea and creatinine concentrations, liver function tests, urine analysis, and pure tone audiograms were performed before treatment, at 25 weeks, and at the end of the study to screen for adverse effects.
ANALYSIS
The data for the two groups were compared by means of the X2 test and the Wilcoxon rank sum test for unpaired data.
Results
Five patients (3 natamycin, 2 placebo) were withdrawn from the study. Two patients, one in each group, with severe pre-existing obstructive airways disease died; one died two weeks after starting placebo and the other died after 11 weeks' natamycin, both with acute exacerbations of their chest disease. A third patient, receiving natamycin, developed wheeze and breathlessness that was related temporally to the study treatment and was withdrawn after 15 weeks. A fourth patient, receiving placebo, was withdrawn after 16 weeks during an acute exacerbation of the aspergillosis with haemoptysis attributed by the patient to the study treatment. The fifth patient, receiving natamycin, was withdrawn after five weeks for non-compliance with the nebuliser treatment. The results are presented for the 20 patients who completed the study.
Prednisolone dosage at 50 weeks was reduced by a similar amount in the two groups (median 2 25 mg natamycin, 2 5 mg placebo) and forced expiratory volume in one second (FEVI) did not alter in either group (table 2) .
Transient chest radiographic shadows were observed on nine occasions (3 natamycin, 6 placebo) in seven patients (3 natamycin, 4 placebo). Blood eosinophilia was observed on 15 occasions (8 natamycin, 7 placebo) in seven patients (2 natamycin, 5 placebo). Specific IgE increased transiently in one placebo treated patient and decreased in one patient receiving natamycin. Specific IgG antibody increased transiently in one patient from each group. Overall, 12 patients (5 natamycin, 7 placebo) had transient radiographic shadows, blood eosinophilia, or an increase in specific immunoglobulins during the study. A fumigatus was cultured from sputum in only one patient in each group. There was a reduction in total IgE in both groups (table 2) but no other change in immunoglobulins.
The patterns of acute exacerbations were reviewed by scrutinising symptoms and signs recorded on the clinical forms and diary cards and the results of investigations. Individual exacerbations could not, however, be reliably categorised into the three expected typesasthma, allergic bronchopulmonary aspergillosis, or acute bronchitis. The median number of exacerbations was similar in the two groups during the study year-natamycin [4] [5] (range 1-10), placebo 5 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) The aim of our study was to reduce the need for corticosteroid suppression of the host inflammatory response by reducing the load of A fumigatus in the lung with prolonged nebulised natamycin treatment. In patients with allergic bronchopulmonary aspergillosis the fungus may be absent from sputum, which makes measurement of the fungal load in the lungs impossible. Hyphae of A fumigatus may not be present in the sputum during acute exacerbations in which A fumigatus is subsequently shown to be present in the lungs. Substantial increases in total or specific IgE have been reported to be useful indicators of an acute exacerbation,'415 but in our study only one transient increase in specific IgE occurred despite radiographic evidence and blood eosinophilia suggesting allergic bronchopulmonary aspergillosis on several occasions.
The reductions of oral corticosteroids in the study were carefully controlled. Inhaled corticosteroids, in the doses taken by the patients in this study, probably do not have an effect on exacerbations of the aspergillosis itself,'6 but do improve control of asthma. Their dosage was not altered during the study. The patients in the study had a long history of allergic bronchopulmonary aspergillosis and required maintenance oral corticosteroids. Despite this treatment there were signs of recent disease activity in most patients. The low initial corticosteroid dosages, the low frequency of acute aspergillosis during the study year, and the small number of patients reduced the power of the study. The frequency of markers of inflammatory activity suggesting allergic bronchopulmonary aspergillosis and the frequency of all types of exacerbations were similar in the two groups during the study. The size of the reduction in oral corticosteroid dosage was similar in the two groups, while the degree of airflow obstruction remained constant. The only significant reductions in antibody levels were for total immunoglobulin E and these occurred in both groups. This finding contrasts with the reduction in IgG and IgE antibodies seen with ketoconazole treatment in the study of ketoconazole in allergic bronchopulmonary aspergillosis,8 though the total IgE and specific IgE levels before treatment in the four patients allocated to ketoconazole were considerably higher than those in the three placebo patients.8
Thus nebulised natamycin treatment for one year did not have a steroid sparing effect in patients with allergic bronchopulmonary aspergillosis whose disease was longstanding and relatively well controlled by oral corticosteroids, and from whose sputum A fumigatus was seldom grown.
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